Fig. 1

Activity and immune biomarkers of pembrolizumab in combination with azacitidine. A Percent change from baseline by RECIST 1.1 at each restaging time point by computed tomography. B Best response seen by RECIST 1.1. C Swimmers plot of treatment course of each patient in the intent to treat population. Immunohistochemistry of immune biomarkers in pre-treatment and on-treatment samples are indicated by numbers in adjacent table. The following were scored based on overall staining strength on scale of + 1 to + 3: TIL PD-L1 pre, TIL PD-L1 post, CD8⁺ TIL pre, CD8⁺ TIL post, FOXP3⁺ pre, FOXP3⁺ post, PD-1 pre, PD-1 post. The following were scored using a modified H-score (0 to 300): tumor PD-L1 pre, tumor PD-L1 post, NY-ESO-1. N/A is not assessed due to either no evaluable tumor or no biopsy obtained. CD8⁺ TIL and PD-1 indicate only intratumoral staining, does not include stromal or tumor/stroma interface staining. FOXP3⁺ are all intratumoral or stromal FOXP3⁺ Treg, although almost every sample had FOXP3 at the tumor/stroma interface. See Additional file 1: methods for additional details